LOG IN
SIGN UP
News
ATOS
0.7249
+2.53%
0.0179
Tech group Atos says Airbus dropping offer for minority stake in its Evidian arm
NASDAQ · 3d ago
Atossa Therapeutics GAAP EPS of -$0.21 beats by $0.01
Seeking Alpha · 03/22 20:49
Atossa Therapeutics Announces Year-End 2022 Financial Results And Provides Corporate Update; As Of December 31, 2022, We Had Cash, Cash Equivalents And Restricted Cash Of $111,000
Benzinga · 03/22 20:32
BRIEF-Atossa Therapeutics Announces Year-End 2022 Financial Results
Reuters · 03/22 20:28
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS) and Karuna Therapeutics (KRTX)
TipRanks · 03/22 12:20
Atossa Therapeutics, Quantum Leap Healthcare Launch New Study Arm for (Z)-Endoxifen to Treat Breast Cancer
Atossa Therapeutics, Quantum Leap Healthcare Launch New Study Arm for (Z)-Endoxifen to Treat Breast Cancer
MT Newswires · 03/21 14:50
Atossa Therapeutics And Quantum Leap Healthcare Announce New Study Arm To Evaluate (Z)-Endoxifen In The Ongoing I-SPY 2 Clinical Trial
Benzinga · 03/21 13:16
BRIEF-Atossa Therapeutics Says Does Not Hold Cash Deposits Or Securities At Silicon Valley Bank
Reuters · 03/13 13:42
Atos expects revenue growth between -1% and 1% in 2023
NASDAQ · 02/28 18:30
Atossa Therapeutics FY 2022 Earnings Preview
Seeking Alpha · 02/28 17:58
Notable earnings before Wednesday's open
Seeking Alpha · 02/28 15:05
Maxim Group Sticks to Its Buy Rating for Atossa Therapeutics (ATOS)
TipRanks · 02/24 18:15
Tech group Atos gets indicative offer from Airbus for minority stake in its Evidian arm
NASDAQ · 02/16 06:02
Atossa announces new U.S. patent covering lead asset
Seeking Alpha · 02/13 16:07
Atossa Therapeutics Gets US Patent for Endoxifen; Shares Rise
Atossa Therapeutics Gets US Patent for Endoxifen; Shares Rise
MT Newswires · 02/13 15:01
Atossa Therapeutics Further Strengthens Intellectual Property Portfolio With Additional Broad Patent For Endoxifen
Benzinga · 02/13 14:17
BRIEF-Atossa Therapeutics Issues Letter To Shareholders
Reuters · 01/25 14:17
Atossa Therapeutics to Enroll 175 Patients for Mid-Stage Breast Cancer Trial
Atossa Therapeutics to Enroll 175 Patients for Mid-Stage Breast Cancer Trial
MT Newswires · 01/25 12:52
BRIEF-Atossa Therapeutics Announces The Appointment Of Eric Van Zanten As Vice President, Investor And Public Relations
Reuters · 12/07/2022 13:42
BRIEF-Atossa Therapeutics Reports Q3 Loss Per Share Of $0.06
Reuters · 11/07/2022 21:54
More
Webull provides a variety of real-time ATOS stock news. You can receive the latest news about Atossa Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATOS
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines in areas of unmet medical need in oncology with a focus on breast cancer. The Company’s lead drug candidate under development is oral (Z)-endoxifen, which the Company is developing in two settings: one to treat breast cancer by reducing tumor cell activity prior to surgery and another to reduce breast tissue density in women. Its programs under development include (Z)-endoxifen Programs, AT-H201, and other programs. (Z)-endoxifen is an active metabolite of tamoxifen, to treat and prevent breast cancer in high-risk women. It is developing a form of (Z)-endoxifen, which is administered orally for the potential treatment of breast cancer and reduction of breast density. AT-H201 is for lung injury caused by cancer treatments. AT-H201 consists of a combination of two drugs to treat other diseases. Its other programs include Immunotherapy/CAR-T Programs, which is in early stage of development.